Fate Therapeutics to Present at 2024 Cantor Global Healthcare Conference

Rhea-AI Summary

Fate Therapeutics (NASDAQ: FATE), a clinical-stage biopharmaceutical company, has announced its participation in the 2024 Cantor Global Healthcare Conference. The company, which focuses on developing iPSC-derived cellular immunotherapies for cancer and autoimmune diseases, will present on Thursday, September 19, 2024, at 12:45 PM ET in New York.

Investors and interested parties can access a live webcast of the presentation through the 'Events & Presentations' section of Fate Therapeutics' website. The archived version will be available shortly after the event concludes. This conference appearance provides an opportunity for Fate Therapeutics to showcase its innovative pipeline and progress in the field of cellular immunotherapies to a global audience of healthcare professionals and investors.

SAN DIEGO, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that the Company will present at the 2024 Cantor Global Healthcare Conference on Thursday, September 19, 2024 at 12:45 PM ET in New York, New York.

A live webcast, if recorded, of the presentation can be accessed under “Events & Presentations” in the Investors section of the Company’s website at www.fatetherapeutics.com. The archived webcast will be available on the Company’s website shortly after the event.

About Fate Therapeutics, Inc.
Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases. Using its proprietary iPSC product platform, the Company has established a leadership position in creating multiplexed-engineered master iPSC lines and in the manufacture and clinical development of off-the-shelf, iPSC-derived cell products. The Company’s pipeline includes iPSC-derived natural killer (NK) cell and T-cell product candidates, which are selectively designed, incorporate novel synthetic controls of cell function, and are intended to deliver multiple therapeutic mechanisms to patients. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com.

Contact:
Christina Tartaglia
Precision AQ
212.362.1200
christina.tartaglia@precisionaq.com

FAQ

When is Fate Therapeutics (FATE) presenting at the 2024 Cantor Global Healthcare Conference?

Fate Therapeutics (FATE) is scheduled to present at the 2024 Cantor Global Healthcare Conference on Thursday, September 19, 2024, at 12:45 PM ET in New York.

How can investors access Fate Therapeutics' (FATE) presentation at the 2024 Cantor Global Healthcare Conference?

Investors can access a live webcast of Fate Therapeutics' (FATE) presentation through the 'Events & Presentations' section in the Investors area of the company's website at www.fatetherapeutics.com.

What type of therapies is Fate Therapeutics (FATE) developing?

Fate Therapeutics (FATE) is developing induced pluripotent stem cell (iPSC)-derived cellular immunotherapies for patients with cancer and autoimmune diseases.

Will the webcast of Fate Therapeutics' (FATE) presentation be available after the event?

Yes, an archived version of the webcast will be available on Fate Therapeutics' (FATE) website shortly after the event concludes.